Chinese Firm Hit With Pandemic's First Remote-Records-Based FDA Drug GMP Warning Letter
Executive Summary
Import alert and warning letter came after Ningbo, China, over-the-counter skin care products firm failed to share requested testing records.
You may also be interested in...
Pre-work Rigor, 'Clean' Documentation Are Key As US FDA Unlocks Remote Inspection Tools
A senior Parexel executive and ex-FDA pharmaceutical quality assessor emphasizes at a conclave why “first impressions matter now more than ever” as the agency deploys complex alternate inspections tools which the pandemic provided, and that companies need to ensure that they get things right the first time.
Pre-work Rigour, 'Clean' Documentation Key As FDA Unlocks Remote Inspection Tools
A senior Parexel executive and ex-FDA pharmaceutical quality assessor emphasizes at a conclave why “first impressions matter now more than ever” as the agency deploys complex alternate inspections tools which the pandemic provided, and that companies need to ensure that they get things right the first time.
Time To Focus On GMP Activities Deferred By Pandemic, CDER Compliance Director Says
US FDA’s Donald Ashley recaps past year’s precedent-setting responses to COVID-19 pandemic in interview, while outlining return to pre-COVID priorities and traditional inspection-based oversight.